PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Rhea-AI Summary

PolyPid (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The virtual event is scheduled for February 11-12, 2025.

The company's presentation will be available on-demand starting Wednesday, February 12, 2025, at 11:20 AM Eastern Time and will remain accessible for 365 days through the conference platform. PolyPid's management team will also conduct one-on-one investor meetings during the event. Interested investors can arrange meetings through their Oppenheimer representative.

PETACH TIKVA, Israel, Jan. 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s management will present at the Oppenheimer 35^th Annual Healthcare Life Sciences Conference taking place virtually on February 11 - 12, 2025.

Oppenheimer 35^th Annual Healthcare Life Sciences Conference

PolyPid’s presentation will be available on-demand beginning on Wednesday, February 12, 2025 at 11:20 AM Eastern Time  and for 365 days after via the conference platform or using the following link.

The PolyPid management team will participate in one-on-one investor meetings during this event. Investors interested in meeting with PolyPid at the conference should contact their Oppenheimer representative.

About PolyPid

PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX₁₀₀ is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.

For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

Contacts:
PolyPid Ltd. 
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com

Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
britchie@lifesciadvisors.com

FAQ

When is PolyPid (PYPD) presenting at the Oppenheimer Healthcare Conference 2025?

PolyPid will present on Wednesday, February 12, 2025, at 11:20 AM Eastern Time.

How long will PolyPid's (PYPD) Oppenheimer Conference presentation be available to view?

The presentation will be available on-demand for 365 days after the initial presentation date.

Is the Oppenheimer Healthcare Conference 2025 where PYPD is presenting in-person or virtual?

The Oppenheimer 35th Annual Healthcare Life Sciences Conference is being held virtually.

How can investors arrange meetings with PolyPid (PYPD) management at the Oppenheimer Conference?

Investors interested in meeting with PolyPid should contact their Oppenheimer representative to arrange one-on-one meetings.

What are the dates for the Oppenheimer Healthcare Conference 2025 featuring PYPD?

The conference takes place virtually on February 11-12, 2025.